📊 EXEL Key Takeaways
Is Exelixis, Inc.. (EXEL) a Good Investment?
Exelixis demonstrates exceptional financial health with outstanding profitability metrics (37.6% operating margin, 33.7% net margin) and a zero-debt balance sheet, generating strong free cash flow of $875.8M annually. Net income growth of 50.1% YoY combined with superior returns on equity (36.2%) and assets (27.5%) indicates robust operational execution and efficient capital deployment in the biopharmaceutical sector.
Exelixis shows strong fundamental quality through high operating and net profitability, very strong free cash flow generation, and a debt-free balance sheet with ample liquidity. Revenue growth is moderate rather than explosive, but earnings growth materially outpaced sales, indicating improved operating leverage and strong business efficiency; however, one reported margin figure appears internally inconsistent, which tempers conviction.
Why Buy Exelixis, Inc.. Stock? EXEL Key Strengths
- Outstanding profitability with 33.7% net margin and 37.6% operating margin, well above industry averages for biologics companies
- Zero long-term debt with $482.5M cash and 3.56x current ratio, providing exceptional financial flexibility and downside protection
- Strong free cash flow generation of $875.8M (37.7% FCF margin) supporting reinvestment, potential shareholder returns, and balance sheet strength
- Significant net income growth of 50.1% YoY despite modest revenue growth of 7.0%, indicating operating leverage and improved efficiency
- Exceptional return metrics with 36.2% ROE and 27.5% ROA, demonstrating superior capital efficiency in converting assets to profit
- Strong earnings growth with net income up 50.1% and diluted EPS up 58.0% year over year
- Excellent financial health with $482.49M in cash, no long-term debt, and strong liquidity ratios above 3.5x
- High cash conversion with $884.27M in operating cash flow and $875.84M in free cash flow, supporting resilience and capital flexibility
EXEL Stock Risks: Exelixis, Inc.. Investment Risks
- Low gross margin of 8.2% suggests minimal contribution per unit of revenue, vulnerable to manufacturing cost inflation or pricing pressure
- Modest revenue growth of 7.0% YoY may indicate market saturation, patent cliff exposure, or limited new product traction in the oncology/biologics pipeline
- Significant insider trading activity with 20 Form 4 filings in last 90 days warrants monitoring for potential management valuation concerns
- Revenue growth of 7.0% is solid but not especially high, so future returns depend on sustaining margin strength
- Profitability may be concentrated in a limited set of products or royalty streams, which can increase business concentration risk
- Reported gross profit and gross margin appear inconsistent with operating income and operating margin, creating some uncertainty around data quality
Key Metrics to Watch
- Revenue growth acceleration and pipeline advancement (new drug approvals and market penetration)
- Gross margin expansion or stability amid manufacturing and input cost dynamics
- Free cash flow sustainability and deployment strategy for shareholder value creation
- Revenue growth versus net income growth to confirm earnings quality and durability
- Operating margin and free cash flow margin consistency, especially given the apparent gross margin data anomaly
Exelixis, Inc.. (EXEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 37.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.56x current ratio provides a solid financial cushion.
EXEL Profit Margin, ROE & Profitability Analysis
EXEL vs Healthcare Sector: How Exelixis, Inc.. Compares
How Exelixis, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exelixis, Inc.. Stock Overvalued? EXEL Valuation Analysis 2026
Based on fundamental analysis, Exelixis, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exelixis, Inc.. Balance Sheet: EXEL Debt, Cash & Liquidity
EXEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exelixis, Inc..'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.65 reflects profitable operations.
EXEL Revenue Growth, EPS Growth & YoY Performance
EXEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $539.5M | $118.0M | $0.40 |
| Q2 2025 | $568.3M | $184.8M | $0.65 |
| Q1 2025 | $425.2M | $37.3M | $0.12 |
| Q3 2024 | $471.9M | $1.0M | $0.00 |
| Q2 2024 | $469.8M | $81.2M | $0.25 |
| Q1 2024 | $408.8M | $37.3M | $0.12 |
| Q3 2023 | $411.7M | $1.0M | $0.00 |
| Q2 2023 | $419.4M | $70.7M | $0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exelixis, Inc.. Dividends, Buybacks & Capital Allocation
EXEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exelixis, Inc.. (CIK: 0000939767)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EXEL
What is the AI rating for EXEL?
Exelixis, Inc.. (EXEL) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EXEL's key strengths?
Claude: Outstanding profitability with 33.7% net margin and 37.6% operating margin, well above industry averages for biologics companies. Zero long-term debt with $482.5M cash and 3.56x current ratio, providing exceptional financial flexibility and downside protection. ChatGPT: Strong earnings growth with net income up 50.1% and diluted EPS up 58.0% year over year. Excellent financial health with $482.49M in cash, no long-term debt, and strong liquidity ratios above 3.5x.
What are the risks of investing in EXEL?
Claude: Low gross margin of 8.2% suggests minimal contribution per unit of revenue, vulnerable to manufacturing cost inflation or pricing pressure. Modest revenue growth of 7.0% YoY may indicate market saturation, patent cliff exposure, or limited new product traction in the oncology/biologics pipeline. ChatGPT: Revenue growth of 7.0% is solid but not especially high, so future returns depend on sustaining margin strength. Profitability may be concentrated in a limited set of products or royalty streams, which can increase business concentration risk.
What is EXEL's revenue and growth?
Exelixis, Inc.. reported revenue of $2.3B.
Does EXEL pay dividends?
Exelixis, Inc.. does not currently pay dividends.
Where can I find EXEL SEC filings?
Official SEC filings for Exelixis, Inc.. (CIK: 0000939767) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EXEL's EPS?
Exelixis, Inc.. has a diluted EPS of $2.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EXEL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exelixis, Inc.. has a BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is EXEL stock overvalued or undervalued?
Valuation metrics for EXEL: ROE of 36.2% (sector avg: 15%), net margin of 33.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy EXEL stock in 2026?
Our dual AI analysis gives Exelixis, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is EXEL's free cash flow?
Exelixis, Inc..'s operating cash flow is $884.3M, with capital expenditures of $8.4M. FCF margin is 37.7%.
How does EXEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 33.7% (avg: 12%), ROE 36.2% (avg: 15%), current ratio 3.56 (avg: 2).
Why is EXEL's return on equity (ROE) so high?
Exelixis, Inc.. has a return on equity of 36.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 33.7% net margin.